BlueRun Ventures Portfolio Companies Named to 2024 Future Healthcare 100 List
Continuously searching for next-generation biotech companies that align with industry logic
The 2024 Future Healthcare 100 list was officially released recently. Thanks to its outstanding track record in healthcare investing, BlueRun Ventures took home:
■ Healthcare Early-Stage and Angel Investor of the Year
BlueRun Ventures portfolio companies also made the list:
■ China's Top 100 Innovative Devices and Intelligent Manufacturing — Tian Cheng Technology
■ China's Top 100 Innovative Pharmaceuticals and Biologics — BioMap
■ China's Top 100 Healthcare and Health Innovation Services — Shanzhen
Launched in 2015, the Future Healthcare 100 is China's first list dedicated to unlisted innovative healthcare companies. Developed by VB100, ArteryNet, and Eggshell Research Institute, it aims to identify the Chinese innovators truly representing the future of medicine, uncover the core forces driving the nation's healthcare industry, and accelerate innovation and transformation across the sector. BlueRun Ventures has long kept a close watch on cutting-edge trends in biotech development. The firm remains committed to its early-stage technology investment strategy, backing bold entrepreneurs who are redefining the future.
▶ More Content ◀
Founded in 2005, BlueRun Ventures is a venture capital firm focused on early-stage startups.
The firm currently manages over RMB 15 billion in assets, making it one of the largest early-stage funds in China. It invests primarily at the Pre-A and Series A stages across technology, consumer, and healthcare sectors, and has backed more than 200 startups to date, including Li Auto, Waterdrop, QingCloud, Guazi.com, Qudian, Ganji.com, Energy Monster, Gaussian Robotics, Songguo Mobility, Yuntu Semiconductor, Machenike, CloudSaints Intelligence, Anxinnet Shield, and BioMap, among others.
BlueRun Ventures has been ranked #1 on Zero2IPO's "China Top 30 Early-Stage Investment Institutions" and ChinaVenture's "China Best Early-Stage Venture Capital Firms TOP30," and was named to Preqin's global top 10 VC fund managers for sustained high returns.
The firm has also received numerous honors from media outlets including Forbes China, 36Kr, Cyzone, Caixin Media, CBNweekly, and Jiemian, including "China Early-Stage Investor of the Year," "China Top Venture Capital Firm," "Most Entrepreneur-Friendly Early-Stage Investor," and "Most Influential Early-Stage Investor."